JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis

다국어 초록 (Multilingual Abstract)

Mutations in the calreticulin gene, CALR, have recently been discovered in subsets of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). We investigated Korean patients with ET and PMF to determine the prevalence, and clinical and laboratory correlations of CALR/JAK2/MPL mutations. Among 84 ET patients, CALR mutations were detected in 23 (27.4%) and were associated with higher platelet counts (P = 0.006) and lower leukocyte counts (P = 0.035) than the JAK2 V617F mutation.
Among 50 PMF patients, CALR mutations were detected in 11 (22.0%) and were also associated with higher platelet counts (P = 0.035) and trended to a lower rate of cytogenetic abnormalities (P = 0.059) than the JAK2 V617F mutation. By multivariate analysis, triple-negative status was associated with shorter overall survival (HR, 7.0; 95% CI, 1.6-31.1, P = 0.01) and leukemia-free survival (HR, 6.3; 95% CI, 1.8-22.0, P = 0.004) in patients with PMF. The type 1 mutation was the most common (61.1%) type among all patients with CALR mutations, and tended toward statistical predominance in PMF patients. All 3 mutations were mutually exclusive and were never detected in patients with other myeloid neoplasms showing thrombocytosis. CALR mutations characterize a distinct group of Korean ET and PMF patients. Triple-negative PMF patients in particular have an unfavorable prognosis, which supports the idea that triple-negative PMF is a molecularly high-risk disease.

참고문헌 (Reference)

1 Tefferi A, "Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients" 89 : E121-E124, 2014

2 Wu Z, "The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms" 7 : 48-, 2014

3 Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms" 369 : 2379-2390, 2013

4 Nangalia J, "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2" 369 : 2391-2405, 2013

5 Tefferi A., "Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management" 89 : 915-925, 2014

6 Rumi E, "JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes" 123 : 1544-1551, 2014

7 박상혁, "Incidence, Clinical Features, and Prognostic Impact of CALR Exon 9 Mutations in Essential Thrombocythemia and Primary Myelofibrosis: An Experience of a Single Tertiary Hospital in Korea" 대한진단검사의학회 35 (35): 233-237, 2015

8 Rotunno G, "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia" 123 : 1552-1555, 2014

9 Chen CC, "Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia" 93 : 2029-2036, 2014

10 Andrikovics H, "Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations" 99 : 1184-1190, 2014

11 Lopez JJ, "Crucial role for endoplasmic reticulum stress during megakaryocyte maturation" 33 : 2750-2758, 2013

12 Rumi E, "Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis" 124 : 1062-1069, 2014

13 Michalak M, "Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum" 417 : 651-666, 2009

14 Li B, "Calreticulin mutations in Chinese with primary myelofibrosis" 99 : 1697-1700, 2014

15 Vannucchi AM, "Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms : pathogenetic insight and diagnostic value" 28 : 1811-1818, 2014

16 하정숙, "Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms" 대한진단검사의학회 35 (35): 22-27, 2015

17 Gold LI, "Calreticulin : non-endoplasmic reticulum functions in physiology and disease" 24 : 665-683, 2010

18 Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons" 28 : 1472-1477, 2014

19 Guglielmelli P, "CALR mutations in myeloproliferative neoplasms : hidden behind the reticulum" 89 : 453-456, 2014

20 Shen H, "CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia" 56 : 820-822, 2015

21 Tefferi A, "An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms" 28 : 1407-1413, 2014

22 Chen Q, "Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders" 9 : 272-276, 2007